ART Modulation of Viral Pathogenesis

项目摘要摘要 在美国，大多数感染人类免疫缺陷病毒1型的患者都是长期的(10年以上) 联合抗逆转录病毒疗法(CART)。虽然CART将HIV复制抑制在50拷贝/毫升以下，但不是 CART对卡波西肉瘤相关疱疹病毒(KSHV)口服的长期疗效已知很多 传播、口腔和全身性KS病或潜伏的KSHV水库。我们建议调查这一影响 不同CART成分对KSHV和KS病的影响及长期阻断口服KSHV的目的 传播和治愈艾滋病毒/艾滋病感染者的病毒。具体地说，我们将专注于调制 KSHV的重新激活以及CART药物如何影响KSHV外体/细胞外小泡。这是一场竞争激烈的 响应PA-16-426/“高”或“中”优先艾滋病研究的续签申请--非艾滋病定义 或艾滋病定义癌症(R01)。

Project Summary Abstract The majority of human immune deficiency virus 1 infected patients in the US are on long-term (10+ years) combination antiretroviral therapy (cART). While cART suppresses HIV replication to below 50 copies/ml, not much is known about the long-term effect of cART on Kaposi sarcoma associated herpesvirus (KSHV) oral transmission, oral and systemic KS disease or the latent KSHV reservoir. We propose to investigate the impact that different cART components have on KSHV and KS disease with the long-term aim to interrupt oral KSHV transmission and cure the virus from persons living with HIV/AIDS. Specifically, we will focus on modulating the reactivation of KSHV and how cART drugs affect KSHV exosomes/ extracellular vesicles. This is a competitive renewal application in response to PA-16-426/ "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01).